CLR 131, a a phospholipid drug conjugate (PDC) developed by Cellectar Biosciences, has been granted orphan drug…
Articles by José Lopes, PhD
Although triple therapies with Revlimid (lenalidomide) should be prioritized in patients with relapsed or refractory multiple myeloma (RRMM),…
Adding Darzalex (daratumumab) to a treatment combination of Velcade (bortezomib), Revlimid (lenalidomide), and dexamethasone increased the proportion of newly diagnosed…
Adding Empliciti (elotuzumab) to a regimen including Pomalyst (pomalidomide) and low-dose dexamethasone extended survival and the time without disease…
The investigational immunotherapy AMG 420 lessened tumor burden and led to cancer disappearing in half of the patients with…
An under-the-skin formulation of daratumumab is as effective as its intravenous delivery — marketed as Darzalex — at easing…
The National Institute for Health and Care Excellence (NICE) in England has recommended treatment with Revlimid (lenalidomide)…
New data from a Phase 1 clinical trial show treatment with GlaxoSmithKline‘s investigational antibody-drug conjugate, GSK2857916, was linked to year…
OncoTracker has acquired worldwide rights to a diagnostic test and possible triple combination therapy for patients with multiple myeloma…
The U.S. Food and Drug Administration is delaying its decision on a new drug application (NDA) seeking approval of…